Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   Ook SIRNA

BioPharma« Terug naar discussie overzicht

Ook SIRNA

Volgen
1.786 Posts
Pagina: «« 1 ... 84 85 86 87 88 ... 90 »» | Laatste | Omlaag ↓
  1. ludwig mack 13 maart 2006 17:29
    quote:

    -Anna- schreef:

    [quote=1gustaaf]
    heb verkocht. 100% verdiend. Ben even tevreden zo. Dacht dat ze door zouden stijgen na correctie, maar het is vandaag vrijdag en had wat zakgeld nodig.
    G
    [/quote]

    duurt even. net door de 7 gegaan zonder al te veel moeite. Ik verwacht dat we langzaam door blijven stijgen met af en toe een stapje terug.
    waar gaan we dan naar toe, denk je ? naar de 10 of meer ? projecties etc. zijn er niet ? wil wel weer instappen maar heb nog geen goede reden dan ....... een toekomst wellicht.
  2. [verwijderd] 14 maart 2006 12:02
    Ik weet het echt niet ludwik. Bijkopen is er voorlopig nog niet bij. Vorig jaar hebben analisten al eens berekend dat de fair value $8 was op dat moment. Kijk wat de koers was in december :(

    Het potentieel is enorm, de markten voor hun medicijnen zijn enorm, maar de koers is gewoon nog niet stabiel.

    Ik probeer zelf nu weer een positie voor de wat langere termijn op te bouwen. Een gedeelte heb ik al, en een gedeelte koop ik bij als we rond de 6 komen of als er goed nieuws is.
  3. [verwijderd] 14 maart 2006 14:43
    SAN FRANCISCO, March 14, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sirna Therapeutics (Nasdaq: RNAI), a leading RNAi therapeutics company, has announced its Scientific Advisory Board (SAB). Joining Keith Yamamoto, Ph.D., Executive Vice Dean for Research at the University of California, San Francisco School of Medicine and Chairman of the Sirna SAB are ten world-renowned scientists who bring expertise in key areas that will be invaluable in transitioning Sirna's pipeline programs from discovery to the clinic.

    Chaired by Dr. Yamamoto, the members of the Sirna Scientific Advisory Board are:

    * Jeffrey A. Bluestone, Ph.D., A.W. and Mary Margaret Clausen
    Distinguished Professor of Medicine, Pathology, Microbiology &
    Immunology at the University of California, San Francisco (UCSF). He is
    the Director of the UCSF Diabetes Center, the Immune Tolerance Network,
    and the Juvenile Diabetes Research Foundation Collaborative Center for
    Cellular Therapy. Dr. Bluestone is an expert in diabetes and immunology

    * Beverly Davidson, Ph.D., Roy J. Carver Professor in Internal Medicine
    and Professor in Neurology, Physiology & Biophysics at the University of
    Iowa. Dr. Davidson is an expert in neurodegenerative diseases and the
    therapeutic use of siRNAs

    * Donald Ganem, M.D., Professor, Microbiology/Immunology and Medicine at
    the University of California, San Francisco and a Howard Hughes Medical
    Institute Investigator. Dr. Ganem is an expert in viral diseases

    * Joe W. Gray, Ph.D., Associate Laboratory Director for Life and
    Environmental Sciences at the Lawrence Berkeley National Laboratory
    (LBNL) and the Director of the LBNL Life Sciences Division. Dr. Gray
    also is Adjunct Professor of Laboratory Medicine at the University of
    California, San Francisco (UCSF). Dr. Gray is an expert in neoplastic
    diseases, breast and ovarian cancer in particular

    * Stanley M. Lemon, M.D., Director, Institute for Human Infections and
    Immunity Professor, Departments of Microbiology & Immunology and
    Internal MedicineUniversity of Texas Medical Branch. Dr. Lemon is an
    expert in chronic hepatitis C and innate immunity

    * Richard Locksley, M.D., Herbert and Marion Sandler Distinguished
    Professorship in Asthma Research; Professor of Medicine and
    Microbiology/Immunology, at the University of California, San Francisco
    and a Howard Hughes Medical Institute Investigator. Dr. Locksley is an
    expert in infectious disease and immunology

    * Jerrold M. Olefsky, M.D., Professor of Medicine and Co-Chair, Division
    of Endocrinology & Metabolism at the University of California, San
    Diego. Dr. Olefsky is an expert in type II diabetes and metabolic
    diseases

    * David W. Russell, Ph.D., Eugene McDermott Distinguished Chair in
    Molecular Genetics at the University of Texas Southwestern. Dr. Russell
    is an expert in lipid metabolism and endocrine disorders

    * Xiaodong Wang, Ph.D., George L. MacGregor Distinguished Chair in
    Biomedical Science at the University of Texas Southwestern Medical
    School and a Howard Hughes Medical Institute Investigator. Dr. Wang is
    an expert in apoptosis and the RNA interference mechanism

    * James A. Wells, Ph.D., Harry Wm. and Diana V. Hind Professorship in
    Pharmaceutical Sciences and Professor of Pharmaceutical Chemistry and
    Cellular and Molecular Pharmacology at the University of California, San
    Francisco. Dr. Wells is an expert in molecular recognitions, the
    protein design and site-directed design of small molecule ligands

    "We are very pleased to bring together these key thought leaders to establish the Sirna Scientific Advisory Board," stated Barry Polisky, Sirna Senior Vice President and Chief Scientific Officer. "Their deep insight into the etiology of important human diseases will be instrumental in advancing our therapeutic programs to the clinic. Further, the interest and direct participation of these world class scientists on our SAB reflects the progress we're making in the development of RNAi-based therapeutics."

    "During the past year, Sirna has made important advances in the development of RNAi-based therapeutics," said Dr. Yamamoto. "The completion of the Phase I clinical trial for Sirna-027 in age-related macular degeneration and the demonstration of systemic efficacy in non-human primates leading to the selection of a clinical candidate in hepatitis C has established Sirna as a leading siRNA therapeutics company. I expect that this exceptional SAB will make a significant contribution to Sirna's therapeutic programs and their ultimate success in the clinic."

  4. [verwijderd] 14 maart 2006 14:56
    Dr. Yamamoto

    cc.ucsf.edu/people/yamamoto_keith.html

    Ik vind het opvallen dat er relatief veel mensen in zitten die iets met diabetes enzo doen. Terwijl ze er officieel nog geen programma voor hebben lopen. En ook kanker trouwens. (is het ook iemand opgevalllen dat de ceo heeft aangegeven met anderen dan lilly te praten in zijn presentaties!)
  7. [verwijderd] 23 maart 2006 19:24
    quote:

    Dirk R. Wijnen schreef:

    Sirna krijgt ook klappen de laatste dagen, is daar nieuws over?

    Dirk
    Je bent me net voor, Dirk. In 3 dagen bijna 15% eraf. Het staat op mijn aanschaflijstje van april, maar ik ben toch bang, dat er iets teveel getraded wordt met het aandeel. Vooralsnog blijf ik er even vanaf.

    Psycho
  15. [verwijderd] 3 april 2006 13:39
    Weer zon gevalletje voorkennis vrijdag, bah!

    Nou ja ik heb er nog een leuk aantal.

    GlaxoSmithKline and Sirna Therapeutics Announce Major Alliance in RNAi-Based Therapeutics for Respiratory Disease
    LONDON, PHILADELPHIA and SAN FRANCISCO, April 3, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- GlaxoSmithKline (NYSE: GSK) and Sirna Therapeutics, Inc. (Nasdaq: RNAI) today announced that they are forming an exclusive multi-year strategic alliance focused on discovery, development and commercialisation of novel RNA interference (RNAi)-based therapeutics for respiratory diseases. The alliance combines Sirna's extensive expertise in short interfering RNA (siRNA) chemistry and biology with GSK's industry leading capabilities in the development and commercialisation of novel therapies for respiratory diseases.

    Sirna will receive an initial payment of $12 million, made up as cash and purchase of Sirna common stock, priced at $ 8.36 per share. Under the agreement, Sirna may also receive milestone payments in excess of $700 million for collaboration and clinical development events, as well as royalties on worldwide sales of products which successfully result from the alliance. In addition, Sirna will be eligible to receive contract manufacturing revenues.

    "By combining GSK's pulmonary drug delivery expertise with Sirna's advanced application of RNAi technology, this alliance will expedite the development of novel therapeutics with potential use in a number of respiratory diseases such as asthma and COPD," said Dr. Garth Rapeport, Senior Vice President, Respiratory & Inflammation CEDD, at GSK. "We recognise Sirna's leadership in the area of RNAi-based therapeutics and hope for the potential benefits this research will bring to patients."

    Under the terms of the agreement, Sirna will provide GSK optimised and formulated siRNAs against Sirna and GSK targets. GSK will assume all responsibility for the further preclinical and clinical development of these compounds as well as worldwide commercialisation of products resulting from the alliance.

    "This collaboration is an extraordinary opportunity for us to work with GSK, the world's second largest pharmaceutical company, to develop important new medicines to treat patients with serious respiratory diseases," stated Howard W. Robin, President and CEO of Sirna Therapeutics. "With this collaboration, Sirna continues to successfully execute our strategy to ally selected therapeutic programs or drug targets with pharmaceutical companies that lead the industry in their respective markets."

    Sirna will conduct a live audio webcast conference call to discuss this alliance on April 3, 2006 at 8:30 am ET. To participate over the Internet, go to www.sirna.com. Participants are urged to log on to the web site 15 minutes prior to the scheduled start time to download and install any necessary audio software. To access the live telephonic broadcast, domestic callers should dial (877) 502-9272; international callers may dial (913) 981-5581.

    An audio webcast replay will be available on Sirna's web site, www.sirna.com, for 30 days. Additionally, a telephonic replay of the call will be maintained through midnight, Monday, April 17, 2006. To access the replay, please dial (888) 203-1112 from the U.S. or (719) 457-0820 when calling internationally, using confirmation code 8943556.


  16. [verwijderd] 3 april 2006 13:46
    en dan kan dit er ook nog wel bij :)

    Sirna Therapeutics Granted First Broad siRNA Patent for a Gene Target in the United States
    Patent Covers Any Chemically Modified siRNA Sequence Used Against the Targeted Gene and Sets Precedent for Sirna Therapeutics' Substantial Target Patent Portfolio in the U.S.
    SAN FRANCISCO, April 3, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Sirna Therapeutics, Inc. (Nasdaq: RNAI) a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) will issue Sirna U.S. Patent No. 7,022,828 on April 4, 2006. This is the first siRNA target patent issued in the United States and sets an important precedent for Sirna's entire target patent portfolio.

    The patent covers any chemically modified siRNA targeting I Kappa B kinase-gamma (IKK-gamma). Importantly, the claims of the patent are not limited to a specific siRNA sequence but cover any siRNA sequence used against the gene. In addition, the claims of this patent are not limited to a specific type of chemical modification or structure but cover any chemical modification that can be made to the siRNA. The patent covers blunt-ended siRNAs as well as those with one or more nucleotide overhangs. IKK-gamma is an activator of the NF-kappaB pathway (NF-kb), an important mediator in a host of diseases, such as asthma, arthritis, cancer, chronic inflammation, neurodegenerative diseases and heart disease.

    "We are gratified that the US Patent Office has issued the first broad siRNA target patent to Sirna," said Bharat Chowrira, Ph.D., Vice President, Legal Affairs and Chief Patent Counsel. "We have put tremendous effort into the creation of a fully enabling target patent portfolio. The formation of this target patent estate required the design, synthesis and evaluation of hundreds of siRNAs per target. The issuance of this patent provides further validation of our patent strategy and gives us confidence that our other patents covering over 250 targets will issue in a similar fashion."

    Sirna is the first company to file enabling patents for over 250 important mammalian disease targets including: alpha-synuclein (Parkinson's disease), BACE (Alzheimer's disease), HBV (hepatitis B), HCV (hepatitis C), HD (Huntington's disease), HIV (human immunodeficiency virus), HR (hairless gene), IL-4, IL-13, IL-4 Receptors, IL-13 Receptors (asthma, respiratory diseases), influenza virus (flu virus), NOGO & NOGO Receptors (spinal cord injury), p38 (inflammation), PTP-1B (diabetes, obesity), retinoblastoma 1 (hearing loss), RSV (reparatory syncytial virus) and VEGF (angiogenesis, AMD, diabetic retinopathy, cancer, kidney disease).

    "The issuance of this patent changes the IP landscape in the field of RNAi," stated Howard W. Robin, President and CEO of Sirna Therapeutics. "We believe that the combination of our target patents with our patents in siRNA design, chemistry, synthesis, and manufacturing gives Sirna Therapeutics a dominant intellectual property estate in the field of RNAi-based therapeutics."


  18. [verwijderd] 4 april 2006 09:15
    O jee, Cramer gaat zich er mee bemoeien. 8.38 nabeurs. Kan misschien hard gaan vanmiddag.

    About three weeks ago, Cramer recommended a company called Sirna Therapeutics (RNAI:Nasdaq - commentary - research - Cramer's Take), a biotech company that develops therapeutics based on RNA interference (RNAi) technology.

    The company announced Monday a deal with GlaxoSmithKline (GSK:NYSE - commentary - research - Cramer's Take), and President and CEO Howard Robin joined Cramer to talk about what the deal means for shareholders.

    Robin said the deal would not only improve efforts to treat asthma and chronic pulmonary disease by pairing Sirna's technology with GlaxoSmithKline treatments, but also it would mean significant royalties and milestone payments for his company.

    However, the CEO said that these milestone payments will be stretched out over time between now and when drugs are approved further down the line.

    Robin also said that the market for asthma treatments is growing very fast and is very competitive. But he said the company's technology can be used in a diverse array of treatments, so it is not solely tied to asthma.

    To view Cramer's interview with Robin, click here.

    www.thestreet.com/video/cramerintervi...

1.786 Posts
Pagina: «« 1 ... 84 85 86 87 88 ... 90 »» | Laatste |Omhoog ↑

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
THEON INTERNAT 18,280 +1,04 +6,03%
ASR Nederland 50,840 +2,09 +4,29%
Alfen N.V. 12,800 +0,45 +3,64%
Accsys 0,515 +0,02 +3,00%
Flow Traders 25,760 +0,58 +2,30%
Aegon 6,532 +0,13 +2,00%
TomTom 4,284 +0,05 +1,28%
NN Group 46,060 +0,58 +1,28%
CTP 16,500 +0,20 +1,23%
RANDSTAD NV 38,540 +0,39 +1,02%
ABN AMRO BANK N.V. 17,630 +0,18 +1,00%
SHELL PLC 32,780 +0,31 +0,95%
JDE PEET'S 16,960 +0,15 +0,89%
B&S Group SA 4,305 +0,04 +0,82%
KPN 3,504 +0,03 +0,75%
SBM Offshore 18,350 +0,13 +0,71%
VASTNED 28,400 +0,20 +0,71%
UNILEVER PLC 52,740 +0,36 +0,69%
BESI 117,550 +0,70 +0,60%
ADYEN NV 1.856,800 +10,80 +0,59%
PostNL 1,059 +0,01 +0,57%
ForFarmers 3,575 +0,02 +0,56%
AZERION 1,648 +0,01 +0,49%
NX FILTRATION 3,265 +0,02 +0,46%
INPOST 17,360 +0,07 +0,40%
Sligro 10,780 +0,04 +0,37%
ALLFUNDS GROUP 4,954 +0,02 +0,36%
Wolters Kluwer 178,000 +0,50 +0,28%
ASMI 572,200 +1,60 +0,28%
Galapagos 25,820 +0,06 +0,23%
ING 16,748 +0,04 +0,22%
Avantium 1,896 +0,00 +0,21%
ASML 717,600 +1,40 +0,20%
ACOMO 18,280 +0,02 +0,11%
Van Lanschot Kempen NV 49,100 +0,05 +0,10%
Fagron 20,000 +0,02 +0,10%
PROSUS 45,060 +0,04 +0,09%
ASCX 1.343,29 +1,17 +0,09%
OCI 11,005 +0,01 +0,05%
AEX 947,37 +0,31 +0,03%
NSI 22,300 0,00 0,00%
RENEWI 10,260 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Philips Koninklijke 24,060 -3,02 -11,15%
Vopak 42,320 -3,02 -6,66%
EBUSCO HOLDING 0,631 -0,02 -2,91%
AMG Critical Materials N.V. 15,970 -0,29 -1,78%
UMG 28,360 -0,46 -1,60%
DSM FIRMENICH AG 103,600 -1,65 -1,57%
Air France-KLM 8,564 -0,12 -1,36%
IMCD 148,200 -1,90 -1,27%
Aperam 30,020 -0,36 -1,18%
Arcadis 50,750 -0,60 -1,17%
HEIJMANS KON 34,300 -0,40 -1,15%
Sif Holding 11,260 -0,12 -1,05%
JUST EAT TAKEAWAY 12,810 -0,13 -1,00%
EXOR NV 94,900 -0,80 -0,84%
Eurocommercial Properties 23,900 -0,20 -0,83%
Akzo Nobel 59,300 -0,46 -0,77%
Kendrion 10,420 -0,08 -0,76%
AMX 862,68 -6,11 -0,70%
Corbion 22,980 -0,16 -0,69%
Nedap N.V. 59,600 -0,40 -0,67%
SIGNIFY NV 21,340 -0,14 -0,65%
Brunel 9,460 -0,06 -0,63%
Basic-Fit 22,500 -0,14 -0,62%
CM.COM 6,440 -0,04 -0,62%
AALBERTS NV 36,940 -0,18 -0,48%
ArcelorMittal 27,580 -0,13 -0,47%
Ahold Delhaize 33,880 -0,14 -0,41%
Wereldhave 15,120 -0,06 -0,40%
Pharming 0,885 0,00 -0,34%
RELX 48,490 -0,11 -0,23%
Fugro 14,890 -0,03 -0,20%
TKH 37,500 -0,04 -0,11%
FASTNED 19,980 -0,02 -0,10%
WDP 21,220 -0,02 -0,09%
Heineken 78,640 -0,06 -0,08%
BAM 4,910 0,00 -0,04%
vlag naam koers verschil relatief verschil
AEX 947,37 +0,31 +0,03%
AEX GR 3.723,03 +1,55 +0,04%
DE40 22.844,50 0,00 0,00%
FTSE 100 8.765,07 -1,66 -0,02%
Europe50^ 5.533,84 0,00 0,00%
US30^ 44.580,40 +34,30 +0,08%
Nasd100^ 22.181,80 +16,40 +0,07%
US500^ 6.131,76 +3,91 +0,06%
Japan225^ 39.128,60 -190,30 -0,48%
VD-NEW 17,76 -0,36 -1,97%
#/^ Index indications calculated real time, zie disclaimer